Ferma Blog

Best Pharma Intelligence Platforms in 2026: CI, BD, and Medical Affairs Teams Compared

aravindhakumar.asaithambi@zoomrx.com (Aravindha Kumar Asaithambi) — Mon, 01 Jun 2026 08:47:36 GMT

The pharma intelligence platform market looks fundamentally different in 2026 than it did three years ago. Database subscriptions that defined the category for two decades are no longer the default choice for CI, BD, and NPP teams evaluating their intelligence stack. AI workflow platforms have entered the market and the question has shifted from "which database has the best coverage" to "which platform closes the gap between data and finished deliverable."

From 33,575 Drugs to 5 Targets: How AI Is Transforming Pharma BD Asset Screening in 2026

aravindhakumar.asaithambi@zoomrx.com (Aravindha Kumar Asaithambi) — Sun, 31 May 2026 15:08:55 GMT

Here’s what a real BD asset screen looked like on Ferma.

How Pharma CI Teams Are Automating Competitive Intelligence in 2026 - Without Losing Methodological Control

aravindhakumar.asaithambi@zoomrx.com (Aravindha Kumar Asaithambi) — Sun, 31 May 2026 14:58:29 GMT

Every pharma CI director has heard the pitch: AI will automate your competitive intelligence. Most have also watched that promise collapse under the weight of hallucinated data, uncited claims, and outputs that need more fact-checking than the manual process they were supposed to replace.

Cortellis vs Ferma: The Pharma CI Platform Comparison 2026

aravindhakumar.asaithambi@zoomrx.com (Aravindha Kumar Asaithambi) — Sun, 31 May 2026 14:48:29 GMT

Cortellis has been the default pharma intelligence platform for two decades. If your CI or BD team runs on structured clinical and regulatory data, you almost certainly have a Cortellis subscription. The question pharma teams are asking in 2026 isn't whether Cortellis has value, it's whether the value justifies the synthesis overhead it places on your analysts every single week.

What Is an Agentic Workflow in Pharma? (And Why It’s Replacing Manual CI and BD Research)

aravindhakumar.asaithambi@zoomrx.com (Aravindha Kumar Asaithambi) — Sun, 31 May 2026 14:07:49 GMT

Pharma intelligence teams don’t have a data problem. Cortellis, AlphaSense, GlobalData, and a dozen other platforms deliver more data than any team can meaningfully process. What pharma CI, BD, and NPP teams actually have is a synthesis problem, the gap between raw data and the finished competitive landscape, BD screening package, or conference summary that a leadership team can act on.

Key Highlights from DDW 2023: A Comprehensive Recap!

Ferma — Tue, 26 May 2026 14:10:12 GMT

Digestive Disease Week (DDW) is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy, and GI surgery. DDW provides an invaluable forum for advancing knowledge and understanding of digestive diseases, making it an essential event for anyone working in this field. The DDW 2023 conference was held from May 6 to 9, in Chicago, IL in a hybrid in-person/virtual model.

ASH 2025 Abstracts are out!: Ferma Congress Analysis

Ferma — Tue, 11 Nov 2025 05:00:00 GMT

The 67th American Society of Hematology (ASH) Annual Meeting is happening in Orlando, Florida from December 6-9, 2025. Over 7,400 world-class oral presentations, poster sessions, educational programs, and scientific workshops will take place in the span of four days, in a hybrid in-person/virtual format.

Advancing the Fight Against NSCLC: Key Highlights from AACR 2025

Ferma — Thu, 03 Apr 2025 04:00:00 GMT

TheAACR Annual Meeting 2025is set to unveil groundbreaking advancements in the fight againstnon-small cell lung cancer (NSCLC). This year’s conference will spotlight emerging therapies, novel biomarkers, and cutting-edge research aimed at improving early detection, treatment efficacy, and patient outcomes. Fromcombination strategies for EGFR-Mutated NSCLCtoadvancements in KRAS-Mutated NSCLC, the latest discoveries could reshape the NSCLC treatment landscape. In this blog, we’ll break down the most exciting highlights from AACR 2025 and explore their potential impact on patients, clinicians, and the future of lung cancer care, created byFerma Congress’ new Insights module.